
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences is well-positioned for success with MyoVista Insights, its cloud software platform for ECG data that has already begun commercialization. Additionally, the company has a large market opportunity, as proven by the over 100 million ECG tests performed in the US annually, and multiple potential revenue streams from MyoVista Insights. With a strong monetization framework and a positive risk/reward profile, HeartSciences has the potential to generate substantial revenues and deliver significant upside to investors.
Bears say
HeartSciences is expected to face a prolonged period of low sales and high expenses as they wait for FDA approval for their product, with revenue estimates for FY2026-2027 being lowered to $0.0 million and $0.4 million respectively. While the recent announcement of FDA 510(k) submission for their MyoVista wavECG device is a positive step, it will still take until early 2026 for approval, keeping the company's future prospects uncertain.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares